DCM
SKYE icon

Driehaus Capital Management’s Skye Bioscience SKYE Stock Holding History

Driehaus Capital Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-77,549
Closed -$2.44M – 501
2025
Q3 		$2.44M Hold
77,549
– – 0.02% 342
2025
Q2 		$2.59M Hold
77,549
– – 0.02% 321
2025
Q1 		$986K Sell
77,549
-3,796
-5% -$82.9K 0.01% 346
2024
Q4 		$1.84M Hold
81,345
– – 0.02% 312
2024
Q3 		$2.54M Hold
81,345
– – 0.02% 296
2024
Q2 		$5.21M Buy
+81,345
New +$7.72M 0.05% 257

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Driehaus Capital Management's SKYE Position: Q4 2025 in Review

Driehaus Capital Management sold out of Skye Bioscience (SKYE) in Q4 2025, closing a stake of 77,549 shares — an estimated $2.44M sold.

Driehaus Capital Management first reported a position in SKYE in Q2 2024 and held it in 6 quarters. The position peaked at $5.21M in Q2 2024. 42 funds tracked by Wall St. Rank hold SKYE as of Q4 2025.

  • Driehaus Capital Management reported no remaining Skye Bioscience position as of Q4 2025 after selling out during the quarter.
  • Driehaus Capital Management sold 77,549 Skye Bioscience shares in Q4 2025, an estimated $2.44M.
  • Driehaus Capital Management first reported a position in Skye Bioscience in Q2 2024 and held it in 6 quarters.
  • Driehaus Capital Management's Skye Bioscience position peaked at $5.21M in Q2 2024.
  • 42 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2025.

Based on Driehaus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.